RE:RE:Paladin sales This is from the Endo 10-K.
"Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin"
In 2018 Endo's International Pharmaceuticals segment had revenue of $142.5 million. Based on that alone I think it's safe to say Paladin's sales are now around $130 million to $150 million. Worth noting also that international adjusted net income was $59.1 million.